Mylan Resolves Shire Suit Over Generic Fosrenol

Law360, New York (June 22, 2011, 6:34 PM EDT) -- Shire US Inc. on Tuesday ended its patent infringement suit in New York against Mylan Inc. and Matrix Laboratories Ltd. over a generic version of the drug Fosrenol, which reduces phosphate levels in the blood of kidney disease patients. 

U.S. District Judge Paul Gardephe dismissed all claims and counterclaims in the case without prejudice as per a stipulation motion from the parties, which agreed to pay their own attorneys' fees and costs. 

The sides also said that that a stay on U.S. Food and Drug Administration...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.